Evelo Biosciences to Host KOL Discussion on Treatment Advances for All Stages of Psoriasis and Potential of SINTAX Medicines
March 07 2022 - 6:00AM
Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage
biotechnology company developing SINTAX™ medicines as a new
modality of orally delivered treatments for inflammatory disease,
today announced that it will host a virtual event titled,
“
The Future: A no regrets treatment for all stages
of psoriasis and broader inflammatory disease.” The event will be
held virtually on Friday, March 11, 2022, beginning at 8:00 a.m.
ET.
During the event, members of Evelo’s leadership, Bruce Strober,
M.D., Ph.D., FAAD, and Clinical Professor of Dermatology at Yale
University School of Medicine and Central Connecticut Dermatology
Research, and Daniel Roling, M.D., Associate Professor of
Dermatology at University of Pennsylvania School of Medicine, will
discuss the unmet need in the treatment of psoriasis and the
potential for SINTAX medicines.
A live webcast of the event will be available under “News and
Events” in the Investors section of Evelo's website
at http://ir.evelobio.com. The archived webcast will be
available on Evelo's website approximately two hours after
completion of the event and will be available for 30 days following
the event.
About Evelo BiosciencesEvelo
Biosciences is a clinical stage biotechnology company
developing orally delivered product candidates that are designed to
act on the small intestinal axis, SINTAX™, with systemic
therapeutic effects. SINTAX plays a central role in governing the
immune, metabolic, and neurological systems. The Company’s first
product candidates are pharmaceutical preparations of single
strains of microbes selected for their potential to offer defined
pharmacological properties. Evelo’s therapies have the potential to
be effective, safe, and affordable medicines to improve the lives
of people with inflammatory diseases.
Evelo currently has three product candidates in development:
EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory
diseases. Evelo is advancing additional product candidates in other
disease areas.
For more information, please
visit www.evelobio.com and engage with Evelo
on LinkedIn.
ContactsInvestors:Kendra Sweeney,
239-877-7474|ksweeney@evelobio.com
Media:Jessica Cotrone,
978-760-5622jcotrone@evelobio.com
Evelo Biosciences (NASDAQ:EVLO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evelo Biosciences (NASDAQ:EVLO)
Historical Stock Chart
From Apr 2023 to Apr 2024